Labocanna

Labocanna EBITDA Margin

The EBITDA Margin of Labocanna (LCN.WA) as of Oct 24, 2026 is -7.73 %. In the previous year, EBITDA Margin was -9.29 % — a change of -16.86% (higher).

EBITDA Margin

-7.73 %

YoY

-16.86%

Last updated:

EBITDA Margin of Labocanna is 2025 -7.73 % . EBITDA Margin of Labocanna was 2024 -9.29 % . It decreases by -16.86% higher compared to the previous year.

The Labocanna EBITDA Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA Margin
Date
EBITDA Margin
Jan 1, 2018
-56.83 PLN
Jan 1, 2019
-377.78 PLN
Jan 1, 2020
425.00 PLN
Jan 1, 2021
-57.58 PLN
Jan 1, 2022
-4,392.24 PLN
Jan 1, 2023
-2,499.62 PLN
Jan 1, 2024
-9.29 PLN
Jan 1, 2025
-7.73 PLN
The Labocanna EBITDA Margin history
YEAREBITDA MarginYoY
-7.73 %-16.86%
-9.29 %-99.63%
-2,499.62 %-43.09%
-4,392.24 %+7,528.62%
-57.58 %-113.55%
425.00 %-212.50%
-377.78 %+564.74%
-56.83 %+399.22%
-11.38 %+24.57%
-9.14 %-180.98%
11.28 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Labocanna Stock analysis

What does Labocanna do? Labocanna SA is a pharmaceutical company based in Koszalin, Poland, operating within the Health Care sector. The company's primary focus is on the hemp business, as indicated by its operational description. It completed its initial public offering (IPO) on July 4, 2011, marking its entry into the public market. Labocanna SA is listed under the ticker symbol LCN.WA and holds the ISIN code PLCCTLS00017. The company's headquarters are located in Koszalin, a city in the West Pomeranian Voivodeship (Woj. Zachodniopomorskie) of Poland. Its official website is https://labocanna.pl/, which serves as a primary source of information about its operations and offerings. The company operates within the pharmaceutical industry, though specific details about its products, services, or market position are not provided in the available information. Labocanna SA's activities are centered around the hemp sector, which may include the development, production, or distribution of hemp-related products, though the exact nature of these activities remains unspecified. The company's public listing and headquarters location are key identifiers for its operational and financial profile. No additional details regarding founding year, key personnel, acquisitions, or financial figures are included in the provided data. Labocanna is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Labocanna stock

EBITDA Margin of Labocanna is -7.73 % in 2025.

EBITDA Margin of Labocanna changed from -9.29 % to -7.73 %, representing a -16.86% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA Margin Labocanna since 2006 – with annual values, charts, and detailed analysis.

EBITDA Margin shows what percentage of revenue converts to EBITDA. It normalizes for depreciation and capital structure differences.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBITDA Margin's Labocanna with sector peers and the industry average to assess whether it is attractive.

To evaluate EBITDA Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBITDA Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Labocanna

All Key Metrics — Labocanna